Frenkel Ronald E, Noecker Robert J, Craven E Randy
Bascom Palmer Eye Institute, Miami, FL, USA.
Curr Med Res Opin. 2008 Apr;24(4):919-23. doi: 10.1185/030079908x273381. Epub 2008 Feb 8.
To compare circadian control of intraocular pressure (IOP) after a single drop of bimatoprost 0.03% or travoprost 0.004% in patients with glaucoma or ocular hypertension.
Randomized, investigator-masked, paired-eye, 36-hour clinical comparison. After completing a washout, patients (N = 19) were randomized to a single drop of bimatoprost in one eye and travoprost in the other eye at 8 PM. At night, IOP was measured with patients lying in bed and sitting. IOP was measured every 4 h for 36 h in total.
Mean IOP at 8 PM (prior to drop instillation) was 20.6 mmHg (18.5-24.0 mmHg) with the bimatoprost eye group and 21.1 mmHg (18.5-26.5 mmHg) with the travoprost eye group (p = 0.369). At every measurement, both bimatoprost and travoprost significantly reduced IOP from baseline. During the first 24 h, mean IOP (while sitting) after instillation of a single drop of study medication ranged from 17.8 to 19.7 mmHg with bimatoprost and from 17.2 to 20.0 mmHg with travoprost (p > or = 0.075). While in the supine position, IOP ranged from 21.6 to 24.9 mmHg with bimatoprost and from 21.1 to 25.2 mmHg with travoprost (p > or = 0.351). Both medications continued to control IOP for the remaining 12 h, with IOP approaching baseline after 36 h (mean IOP of 20.5 mmHg with bimatoprost and 21.5 mmHg with travoprost, p = 0.381). Study limitations included single-drop instillation and a short follow-up time.
This marks the first time a single drop has been used for this type of evaluation. These findings suggest that both bimatoprost and travoprost provide comparable and lasting control of circadian IOP in patients with glaucoma or ocular hypertension.
比较0.03%比马前列素或0.004%曲伏前列素单滴用药后青光眼或高眼压症患者眼压的昼夜控制情况。
随机、研究者设盲、双眼配对、36小时临床比较。洗脱期结束后,19例患者于晚上8点一眼滴入单滴比马前列素,另一眼滴入单滴曲伏前列素。夜间,测量患者卧位及坐位时的眼压。共36小时内每4小时测量一次眼压。
晚上8点(滴药前),比马前列素眼组平均眼压为20.6 mmHg(18.5 - 24.0 mmHg),曲伏前列素眼组为21.1 mmHg(18.5 - 26.5 mmHg)(p = 0.369)。每次测量时,比马前列素和曲伏前列素均使眼压较基线水平显著降低。在最初24小时内,单滴研究药物滴入后,比马前列素组坐位时平均眼压在17.8至19.7 mmHg之间,曲伏前列素组在17.2至20.0 mmHg之间(p≥0.075)。仰卧位时,比马前列素组眼压在21.6至24.9 mmHg之间,曲伏前列素组在21.1至25.2 mmHg之间(p≥0.351)。两种药物在剩余12小时内均持续控制眼压,36小时后眼压接近基线水平(比马前列素组平均眼压为20.5 mmHg,曲伏前列素组为21.5 mmHg,p = 0.381)。研究局限性包括单滴用药及随访时间短。
这是首次将单滴用药用于此类评估。这些发现表明,比马前列素和曲伏前列素在青光眼或高眼压症患者中对眼压昼夜变化提供了相当且持久的控制。